Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome

被引:0
|
作者
Xiao-ling Wu
Ding Long
Li Yu
Jun-hui Yang
Yuan-chao Zhang
Feng Geng
机构
[1] Intensive Care Unit
[2] Wuhan Central Hospital
[3] Tongji Medical College
[4] Huazhong University of Science and
关键词
D O I
暂无
中图分类号
R459.7 [急症、急救处理];
学科分类号
100218 ;
摘要
BACKGROUND:Urokinase-type plasminogen activator(uPA) and urokinase-type plasminogen activator receptor(uPAR) are known as important factors,which mediate a variety of functions in terms of vascular homeostasis,inflammation and tissue repair.However,their role in systemic inflammatory response syndrome(SIRS) has been less well studied.This study aimed to test the hypothesis that the abnormalities of fibrinolysis and degradation of extracellular matrix mediated by uPA and uPAR are directly related to the patients with SIRS.We therefore analyzed their role and clinicopathological significance in patients with SIRS.METHODS:A case-control study was conducted with 85 patients who were divided into two groups according to the diagnostic criteria of SIRS:SIRS group(n=50) and non-SIRS group(/7=35).The SIRS group was divided into MODS group(n=26) and non-MODS group(n=24) by their severity,and survival group(n=35) and non-survival group(n=15) by their prognosis.Another 30 healthy adults served as normal controls.uPA and uPAR in plasma were detected by commercial enzyme-linked immunosorbent assay(ELISA) kits.RESULTS:The plasma level of uPA was lower in the SIRS group than in the non-SIRS group and controls(P<0.001 and P<0.001).It was lower in sepsis patients and the MODS group than in the non-sepsis patients and the non-MODS patients(all P<0.05).However,there was no difference in uPA level between survivors and non-survivors(P>0.05).The plasma level of uPAR increased in the SIRS group compared with the non-SIRS group and controls(P<0.001 and P<0.001).There was a significant elevation of uPAR in sepsis patients,MODS patients and non-survivors as compared with non-sepsis patients,non-MODS patients and survivors respectively(all P<0.05).Plasma uPAR levels were positively correlated with APACHE Ⅱ score(r=0.575,P<0.001) and SOFA score(r=0.349,P=0.013).AUCs for the prediction of SIRS mortality were 0.67 and 0.51,respectively,for uPA and uPAR.CONCLUSION:uPAR could be a predictor of poor outcome in patients with SIRS.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 50 条
  • [21] The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome
    Yilmaz, Gurdal
    Koksal, Iftihar
    Karahan, S. Caner
    Mentese, Ahmet
    CLINICAL BIOCHEMISTRY, 2011, 44 (14-15) : 1227 - 1230
  • [22] A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor And Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome
    Sharma, Ankita
    Ray, Sumit
    Mamidipalli, Ramya
    Kakar, Atul
    Chugh, Parul
    Jain, Ridhima
    Ghalaut, Manvender S.
    Choudhury, Sangeeta
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2020, 24 (04) : 245 - 251
  • [23] The urokinase-type plasminogen activator system and inflammatory joint diseases
    Del Rosso, M
    Fibbi, G
    Cerinic, MM
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (04) : 485 - 498
  • [24] Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system
    Yin, SP
    Lockett, J
    Meng, YH
    Biliran, H
    Blouse, GE
    Li, XH
    Reddy, N
    Zhao, ZM
    Lin, XL
    Anagli, J
    Cher, ML
    Sheng, SJ
    CANCER RESEARCH, 2006, 66 (08) : 4173 - 4181
  • [25] Soluble Urokinase-type Plasminogen Activator Receptor as a marker of outcome in severe sepsis.
    Adamik, B.
    Lipinska-Gediga, M. B.
    Kuebler, A.
    INFECTION, 2011, 39 : S120 - S120
  • [26] Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer
    Kaneko, T
    Konno, H
    Baba, M
    Tanaka, T
    Nakamura, S
    CANCER SCIENCE, 2003, 94 (01) : 43 - 49
  • [27] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Chung, HC
    Rha, SY
    Park, JO
    Yoo, NC
    Kim, JH
    Roh, JK
    Min, JS
    Lee, KS
    Kim, BS
    Kim, JJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (01) : 41 - 50
  • [28] Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
    Renáta M. Böcskei
    Béla Benczúr
    György Losonczy
    Miklós Illyés
    Attila Cziráki
    Veronika Müller
    Anikó Bohács
    András Bikov
    Lung, 2019, 197 : 189 - 197
  • [29] Novel protein interactors of urokinase-type plasminogen activator receptor
    Mekkawy, Ahmed H.
    De Bock, Charles E.
    Lin, Zhen
    Morris, David L.
    Wang, Yao
    Pourgholami, Mohammad H.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 399 (04) : 738 - 743
  • [30] Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
    Hyun Cheol Chung
    Sun Young Rha
    Joon Oh Park
    Nae Choon Yoo
    Joo Hang Kim
    Jae Kyung Roh
    Jin Sik Min
    Kyong Sik Lee
    Byung Soo Kim
    Jin Ju Kim
    Breast Cancer Research and Treatment, 1998, 49 : 41 - 50